Menu
Scroll to top
Topic: Pharmaceutical Benefits Scheme
Keane: grand final or no, funding sport is a complete waste of money

Keane: grand final or no, funding sport is a complete waste of money

Australia wastes billions of taxpayer dollars on elite sports funding and major sporting events for no benefit whatsoever. It's time to end it.

PBS: time for high-income earners to pay more

PBS: time for high-income earners to pay more

Reforming the PBS should involve high-income earners paying more for medicines -- but there are significant implementation issues.

Tackling health waste is about more than ‘a few bad apples’

Tackling health waste is about more than ‘a few bad apples’

Too often we seem to forget in debates about our mythical "health system" that much healthcare is provided by private interests, whether private practitioners or companies.

Australia is falling behind in affordable medicines

Australia is falling behind in affordable medicines

The Pharmaceutical Benefits Scheme (PBS) has served Australians well for many years but recent policy changes are undermining the universality of this important health program, writes Jennifer Doggett.

Forget Murdoch, worry about Europe’s sovereign debt crisis

Forget Murdoch, worry about Europe’s sovereign debt crisis

I fear the really important drama from the northern hemisphere is the continuing sovereign debt crisis, not News of the World.

13 new drugs for the PBS, but Roxon has a long way to go

13 new drugs for the PBS, but Roxon has a long way to go

Federal Health Minister Nicola Roxon’s announcement of the addition of 13 new drugs to the Pharmaceutical Benefits Scheme comes as a huge relief.

How the government can get serious about cutting PBS spending

How the government can get serious about cutting PBS spending

The cost of the PBS must be sustainable but there is a difference between saving money and ensuring cost-effectiveness. The treatment of macular degeneration provides a compelling example, writes Ken Harvey, Richard Day, Willie Campbell, and Wendy Lipworth.

Paying for health care: how can we sustain it?

Paying for health care: how can we sustain it?

The constraints on public sector financing mean governments will need to play a more active role in determining what will, and will not, be funded in health care, writes Anne-marie Boxall.

‘My’ MS, a magic pill, and what the PBS fight means to me

‘My’ MS, a magic pill, and what the PBS fight means to me

The politics of turning the final approval of new medications into a Cabinet decision at the least, delays treatment to patients who may benefit from it. At the worst, it turns them down. Here's what that means for me, and "my MS", writes Shakira Hussein.

The PBS deserves sensible reform

The PBS deserves sensible reform

The government has been taking some heat recently over its decision to defer listing of new medicines on the Pharmaceutical Benefits Scheme (PBS). Perhaps it’s time that some wider reforms of the PBS were considered, says Rebecca de Boer.